Abstract: Novel vectors and methods for a single-stranded DNA mediated gene transfer system via transformation, fusion or transduction of Streptomyces, other actinomycetes, and E. coli using a variety of vectors. Phasmid shuttle vectors of the invention are particularly useful as single-stranded vectors that appear to bypass one or more host cell restriction systems, and thus increase the efficiency of gene transfer into highly restrictive host cell systems. New and useful vectors are provided that allow for the cloning of genes both for increasing the yields of known antibiotics and also for producing new antibiotics, antibiotic derivatives, or any other useful gene product, including a variety of mammalian protein products.
Type:
Grant
Filed:
February 10, 1992
Date of Patent:
February 28, 1995
Assignee:
Eli Lilly and Company
Inventors:
Jeffrey T. Fayerman, Richard K. Stanzak
Abstract: The present invention provides an improvement in injection syringes by providing for an end of dose indicator which is operatively associated with the dose knob of an injection syringe. The instant end of dose indicator works by providing a sound as an indication that the complete dose has been administered.
Abstract: The invention includes recombinant DNA compounds, vectors and methods useful for expressing an exceptionally rare, human, cytosolic phospholipase A.sub.2 (cPLA.sub.2) enzyme. The invention also includes a method for screening compounds to identify inhibitors of cPLA.sub.2 which is believed to partake in several disease processes.
Type:
Grant
Filed:
April 12, 1993
Date of Patent:
July 12, 1994
Assignee:
Eli Lilly and Company
Inventors:
Xue-Chiou C. Chiou, JoAnn Hoskins, Ruth M. Kramer, John D. Sharp, Donald L. White
Abstract: The invention concerns compounds and methods for the recombinant production of a homogeneous population of tissue plasminogen activator molecules and derivatives thereof through the use of heterologous propeptide regions that are uniformly cleaved upon secretion from the host cell.
Abstract: This invention provides trans-3,4 1-substituted-3-substituted-4-methyl-4-(3-substituted phenyl)piperidines as opioid antagonists capable of blocking the mu or kappa receptors in the brain.
Abstract: A method of inhibiting cell proliferation in mammals which comprises the local delivery of an inhibitory amount of dipyridamole. Inhibiting cell proliferation is useful for the treatment of proliferative diseases such as vascular restonesis, scleroderma, psoriasis, and rheumatoid arthritis. This method includes the local delivery of dipyridamole to the proliferative site by various techniques including local delivery catheters, site specific carriers, implants, direct injection, or direct application.
Abstract: New polyether antibiotic A82810, its acyl and alkyl ester, acyl ester and urethane derivatives, and salts thereof, are useful antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A82810 by culture of Actinomodura fibrosa sp. nov. NRRL 18348 and synergistic compositions of the A82810 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and metichlorpindol are also provided.
Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
Type:
Grant
Filed:
September 17, 1991
Date of Patent:
May 17, 1994
Assignee:
Eli Lilly and Company
Inventors:
Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
Abstract: New glycopeptide antibiotic A82846, comprising A82846A, A82846B and A82846C, is produced by Nocardia orientalis strains NRRL 18098, NRRL 18099 and NRRL 18100. The A82846 antibiotics have activity against Gram-positive bacteria comparable to that of vancomycin.
Type:
Grant
Filed:
May 9, 1990
Date of Patent:
May 17, 1994
Assignee:
Eli Lilly and Company
Inventors:
Robert L. Hamill, James A. Mabe, David F. Mahoney, Walter M. Nakatsukasa, Raymond C. Yao
Abstract: The present invention is directed to a method for increasing the milk producing capacity of a female bovidae, by administering an effective amount of an active agent to the bovidae during its mammary glands' allometric growth phase preceding first conception. The active agent is ractopamine or a physiologically acceptable salt.
Abstract: The present invention relates to a hypodermic syringe having the same general appearance as a pen which is specifically adapted to provide for multiple measure injections of materials such as insulin or human growth hormone.
Abstract: The instant invention provides novel molecules derived from the components of proinsulin using recombinant DNA technology. The invention provides molecules of the formula A--C--B wherein A is the A-chain of an insulin species, B is the B-chain of an insulin species and C is a connecting peptide. These molecules possess insulin-like activity and are useful for the treatment of diabetes mellitus, particularly non-insulin dependent diabetes mellitus. These molecules are also useful for the production of insulin and constitute a novel pathway for the recombinant production of insulin species. The invention provides a method of making insulin proceeding through the compounds of the invention as intermediates. The instant invention further provides recombinant DNA compounds which encode the compounds of the invention.
Type:
Grant
Filed:
June 11, 1991
Date of Patent:
April 19, 1994
Assignee:
Eli Lilly and Company
Inventors:
Rama M. Belagaje, Richard D. DiMarchi, William F. Heath, Jr., Harlan B. Long
Abstract: This invention provides certain sulfonamide compounds, formulations and method of use of certain sulfonamide compounds in treating susceptible neoplasms.
Type:
Grant
Filed:
April 29, 1992
Date of Patent:
April 12, 1994
Assignee:
Eli Lilly and Company
Inventors:
J. Jeffry Howbert, Fariborz Mohamadi, Michael M. Spees
Abstract: The present invention provides a novel ester cleavage process for use with .beta.-lactams. The process is useful because of mild conditions necessary to complete the reaction, such conditions being especially suitable for .beta.-lactams.
Abstract: The present invention provides 4-amino-6-substituted-hexahydrobenz[cd]indoles which are useful in treating disease states which can be benefited by an alteration of 5-HT.sub.1A receptors.
Type:
Grant
Filed:
May 27, 1993
Date of Patent:
April 12, 1994
Assignee:
Eli Lilly and Company
Inventors:
Michael E. Flaugh, Michael J. Martinelli
Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
Type:
Grant
Filed:
March 18, 1993
Date of Patent:
April 5, 1994
Assignee:
Eli Lilly and Company
Inventors:
Raymond F. Brown, J. Jeffry Howbert, Karen L. Lobb, David A. Neel, Jon K. Reel, Beverley Greenwood
Abstract: Chiral epoxybutyrates are prepared in high yield from novel dihydro-3R-substituted sulfonyloxy-4R-hydroxy-2-(3H)furanones via based catalyzed alcoholysis. The product chiral epoxy butyrates are useful intermediates for the synthesis of 1-carba-1-dethia cephem antibiotics.
Abstract: Two embodiments of a multi-dose syringe both include structure for indicating the selected amount of liquid to be injected. A first element and a second element coupled respectively to the syringe housing and the plunger rod are adapted for calibrated movement with respect to each other, one of the first and second elements includes an outer portion having dose-indicating scale thereon, and another of the first and second elements surrounding said outer portion includes a window through which only a segment of the dose-indicating scale on said portion is visible, the visible portion indicating the amount of liquid selected for injection.